Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.

Brandon LuWei Fang DaiRuth CroxfordWanrudee IsaranuwatchaiJaclyn BecaInes B MenjakTeresa M PetrellaNicole MittmannCraig C EarleScott GavuraRebecca E MercerTimothy P HannaKelvin Kar-Wing Chan

Published in: Cancer medicine (2023)

Despite its clinical benefit, ipilimumab as second-line monotherapy for MM patients is not cost-effective in the real world as projected by HTA under conventional willingness-to-pay thresholds.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
randomized controlled trial
peritoneal dialysis
climate change
clinical trial
open label
health insurance
combination therapy